Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637897 · ClinicalTrials.gov registry record · Phase 1
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00637897 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 24 participants.
The verdict
NCT00637897, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, docetaxel,, paclitaxel, and ixabepilone work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Paricalcitol may help chemotherapy drugs to kill more tumor cells by making tumor cells more sensitive to the drugs. PURPOSE: This clinical trial is studying the best dose and best way to give paricalcitol and to see how well it works when given together with chemotherapy in treating patients with metastatic breast cancer.
Interventions
- DRUG docetaxel
- DRUG paclitaxel
- DRUG paclitaxel albumin-stabilized nanoparticle formulation
- DRUG ixabepilone
- DRUG paricalcitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637897
The ClinicalTrials.gov registry entry for NCT00637897 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which docetaxel is the first listed.
NCT00637897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637897 about?
NCT00637897 is a clinical study titled "Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, docetaxel,, paclitaxel, and ixabepilone work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Paricalcitol may help chemotherapy d...
What is the current status of trial NCT00637897?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00637897?
The interventions under investigation include: docetaxel (DRUG), paclitaxel (DRUG), paclitaxel albumin-stabilized nanoparticle formulation (DRUG), ixabepilone (DRUG), paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00637897?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.